Serum Institute of India (SII) expects World Health Organization (WHO) emergency-use authorization forthwith for the Oxford University/AstraZeneca coronavirus vaccine, which it is producing for mid and low-income countries, its chief executive said.
"The emergency use licensure from the WHO should be available and coming through in the next week or two, hopefully, because we have submitted everything," Adar Poonawalla told the Reuters Next conference on January 14. Poonawalla added his company, the world's biggest vaccine maker, would start stockpiling millions of doses of the Novavax coronavirus vaccine candidate from around April.
"It will be upwards of 40-50 million doses per month is what we are trying to stockpile of the Novavax product," he said.
The CEO said a special purpose vehicle housing its pandemic-related products should be valued at USD12 billion to USD13 billion.